UNLIMITED TURBO SHORT - BRISTOL-MYERS SQUIBB | Real-time Bid/Ask 15:02:49 17/06/2024 BST | ||
| 3.46 EUR / 3.47 EUR | +1.32% |
|
| 1 month | +11.76% | ||
| 3 months | +44.92% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BRISTOL-MYERS SQUIBB COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 17/06/24 | 3.44 | +0.58% |
| 14/06/24 | 3.42 | +0.59% |
| 13/06/24 | 3.4 | +3.66% |
| 12/06/24 | 3.28 | +0.61% |
| 11/06/24 | 3.26 | -0.91% |
Delayed Quote Börse Stuttgart
Last update June 17, 2024 at 02:51 pm
More quotesStatic data
| Product type | Knock-Out ohne Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | BRISTOL-MYERS SQUIBB COMPANY |
| Issuer | 
BNP Paribas
|
| WKN | PE6RD4 |
| ISIN | DE000PE6RD47 |
| Date issued | 15/12/2022 |
| Strike | 77.81 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 0.34 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.5 € |
|---|---|
| Lowest since issue | 0.28 € |
| Spread | 0.01 € |
| Spread % | 0.29% |
Company Profile
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
Sector
-
Ratings for Bristol-Myers Squibb Company
Trading Rating
Investor Rating
ESG Refinitiv
B
Consensus: Bristol-Myers Squibb Company
Sell
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
41.2
USD
Average target price
53.19
USD
Spread / Average Target
+29.11%
- Stock Market
- Certificates
- Certificat
